Lexicon Pharmaceuticals (NASDAQ:LXRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release. Analysts ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA ...

During the 85th Scientific Sessions, Lexicon also will present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

Get the detailed quarterly/annual income statement for Lexicon Pharmaceuticals, Inc. (LXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript May 13, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.1.

Texas-based biotech Lexicon Pharmaceuticals (NASDAQ:LXRX) was incorporated in 1995, and has been listed on the Nasdaq since 2000. According to a statement in the company's 2022 10K submission ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and ...

Nov 22 (Reuters) - Lexicon Pharmaceuticals (LXRX.O), opens new tab said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its ...

Lexicon Pharmaceuticals announced that it will present data from a study on sotagliflozin's effects on hypoglycemia in individuals with type 1 diabetes at the upcoming American Diabetes ...

Lexicon Pharmaceuticals, Inc. (LXRX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...